Iambic Therapeutics, Inc.

expected

Oct 15, 2026

per news reports

status

Listed

proposed ticker

IAM

The expected listing date (Oct 15, 2026) comes from news reporting, not a regulatory filing — regulators publish a filing or approval date, not the day a company starts trading. See the source. It is replaced automatically if an official date is published.

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

United States

Incorporated in

Overview

— AI-generated from the filing, see note below

Business overview

Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company focused on revolutionizing the biopharmaceutical industry through its proprietary molecular superintelligence platform. This platform integrates advanced artificial intelligence with automated chemistry and biology experimentation to enhance drug discovery and development processes. Current programs include the development of drug candidates targeting various cancer indications, leveraging partnerships with prominent pharmaceutical companies to expand its capabilities.

Revenue model

Not disclosed in the provided filing text.

Competitive strengths

Integration of proprietary AI technologies for molecular property prediction
Automated workflows that allow for rapid synthesis and testing of compounds
Enhanced understanding of druggable spaces through learning from laboratory-generated data
Strategic partnerships with leading pharmaceutical companies to broaden the impact and applicability of its platform

Risk factors

Uncertainty regarding the success of its platform in leading to clinically approved drug products
Dependence on the outcomes of clinical trials that may not yield favorable results
Market competition from established drug discovery methods and technologies
Requirement for significant capital and resources to advance drug candidates through clinical trials

Use of proceeds

Not disclosed in the provided filing text.

This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.

IPO details

The expected date is Oct 15, 2026. The proposed ticker is IAM. Iambic Therapeutics, Inc. is headquartered in United States and incorporated in DE. It is classified under Biological Products, (No Diagnostic Substances).

Estimated post-listing dates

The dates below are calculated from widely-used industry conventions, not from this offering's own disclosed terms — DiscoverIPO does not have a structured source for the actual figures. Treat them as reference points, not confirmed dates.

Lock-up expiry (estimated): Apr 13, 2027, based on a customary 180-day lock-up period. The actual length is set in the underwriting agreement — typically 90 to 180 days — and this offering's real terms may differ.
Quiet period end (estimated): Nov 9, 2026, based on the customary 25-day quiet period convention following a US listing.

Related IPO lists

Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with Iambic Therapeutics, Inc..

Biotech IPOs United States IPOs

Embed this company

Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.

Iframe — WordPress / Ghost / Notion / Webflow

<iframe src="https://www.discoveripo.com/embed/iambic-therapeutics" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="Iambic Therapeutics, Inc. — DiscoverIPO"></iframe>

Dark by default. For a light background, use https://www.discoveripo.com/embed/iambic-therapeutics?theme=light as the src instead.

Share image — Substack, email, anywhere

https://www.discoveripo.com/ipo/iambic-therapeutics/opengraph-image

Attribution text

Iambic Therapeutics, Inc. IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/iambic-therapeutics?utm_source=embed&utm_medium=text&utm_campaign=iambic-therapeutics

Track this IPO

Get emailed when Iambic Therapeutics, Inc.'s terms, price, or expected date change — no weekly noise, just this company.

Frequently asked questions

When is Iambic Therapeutics, Inc. expected to go public?

Iambic Therapeutics, Inc. is expected to list on Oct 15, 2026.

What is Iambic Therapeutics, Inc.'s ticker symbol?

Iambic Therapeutics, Inc.'s proposed ticker is IAM.

Where this data comes from

Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Oct 8, 2026.

View the original filing on SEC EDGAR →

Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.